APA   Click to copy
A., W., P, J., K, M. N., Malka O, D. J., A, V., C, B., … M, H. TH-MYCN tumors convert to a mesenchymal phenotype, lose GD2, and increase inflammatory signaling implications for preclinical immunotherapy.

Chicago/Turabian   Click to copy
A., Wolpaw, Jung P, McNerney K, Dessau J Malka O, Vu A, Burudpakdee C, Bassiri H, and Hogarty M. “TH-MYCN Tumors Convert to a Mesenchymal Phenotype, Lose GD2, and Increase Inflammatory Signaling Implications for Preclinical Immunotherapy,” n.d.

MLA   Click to copy
A., Wolpaw, et al. TH-MYCN Tumors Convert to a Mesenchymal Phenotype, Lose GD2, and Increase Inflammatory Signaling Implications for Preclinical Immunotherapy.

@conference{wolpaw-a,
  title = {TH-MYCN tumors convert to a mesenchymal phenotype, lose GD2, and increase inflammatory signaling implications for preclinical immunotherapy},
  author = {A., Wolpaw and P, Jung and K, McNerney and Malka O, Dessau J and A, Vu and C, Burudpakdee and H, Bassiri and M, Hogarty}
}